摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6,7,8,9-tetrahydro-4-hydroxy-3-(1-phenylpropyl)cycloheptapyran-2(5H)-one

中文名称
——
中文别名
——
英文名称
6,7,8,9-tetrahydro-4-hydroxy-3-(1-phenylpropyl)cycloheptapyran-2(5H)-one
英文别名
6,7,8,9-Tetrahydro-4-hydroxy-3-(1-phenylpropyl)-cyclohepta[b]pyran-2(5H)-one;4-hydroxy-3-(1-phenylpropyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyran-2-one
6,7,8,9-tetrahydro-4-hydroxy-3-(1-phenylpropyl)cyclohepta<b>pyran-2(5H)-one化学式
CAS
——
化学式
C19H22O3
mdl
——
分子量
298.382
InChiKey
YKJXQZGJGDTEOC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    22
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    环庚三烯并[b]吡喃-2(5H)-酮,6,7,8,9-四氢-4-羟基-1-苯丙醇 在 3 A molecular sieve 、 对甲苯磺酸 作用下, 以 甲苯 为溶剂, 反应 7.0h, 以41%的产率得到6,7,8,9-tetrahydro-4-hydroxy-3-(1-phenylpropyl)cycloheptapyran-2(5H)-one
    参考文献:
    名称:
    Use of Medium-Sized Cycloalkyl Rings To Enhance Secondary Binding: Discovery of a New Class of Human Immunodeficiency Virus (HIV) Protease Inhibitors
    摘要:
    A unique strategy for the enhancement of secondary binding of an inhibitor to an enzyme has been demonstrated in the design of new human immunodeficiency virus (HIV) protease inhibitors. When the planar benzene ring of a 4-hydroxycoumarin lead compound (1a, K-1 = 0.800 mu M) was replaced with medium-sized (i.e., 7-9), conformationally-flexible, alkyl rings, the enzyme inhibitory activity of the resulting compounds was dramatically improved, and inhibitors with more than 50-fold better binding (e.g., 5d, K-i = 0.015 mu M) were obtained. X-ray crystal structures of these inhibitors complexed with HIV protease indicated the cycloalkyl rings were able to fold into the S1' pocket of the enzyme and fill it much more effectively than the rigid benzene ring of the 4-hydroxycoumarin compound. This work has resulted in the identification of a promising lead structure for the design of potent, deliverable HIV protease inhibitors. Compound 5d, a small (MW = 324), nonpeptidic structure, has already shown several advantages over peptidic inhibitors, including high oral bioavailability (91-99%), a relatively long half-life (4.9 h), and ease of synthesis (three steps).
    DOI:
    10.1021/jm00011a008
点击查看最新优质反应信息

文献信息

  • 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS
    申请人:THE UPJOHN COMPANY
    公开号:EP0682663A1
    公开(公告)日:1995-11-22
  • [EN] 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL[B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS<br/>[FR] 4-HYDROXY-BENZOPYRANE-2-ONES ET 4-HYDROXY-CYCLOALKYLE-[B]PYRANE-2-ONES UTILES POUR LE TRAITEMENT DES INFECTIONS RETROVIRALES
    申请人:THE UPJOHN COMPANY
    公开号:WO1994018188A1
    公开(公告)日:1994-08-18
    (EN) The present invention relates to compounds of formula (I) which are 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl[b]pyran-2-ones useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus. In formula (I) R10 and R20 taken together are formula (II) or formula (III).(FR) Composés de la formule (I) correspondant à des 4-hydroxy-benzopyrane-2-ones et à des 4-hydroxy-cycloalkyle[b]pyrane-2-ones employés pour l'inhibition d'un rétrovirus dans une cellule de mammifère infectée par ledit rétrovirus. Dans la formule (I) R10 et R20 considérés ensemble sont (II) ou (III).
查看更多

同类化合物

3-羟基-8,9,10,11-四氢-7H-环庚基色烯-6-酮 2-(3,4-亚甲二氧基苯基)环庚三烯并[b]吡喃-4,9-二酮 irosustat 2,4-dibromo-3-hydroxy-7,8,9,10-tetrahydro-benzo[c]chromen-6-one 2-phenyl-4H-thiopyrano[3,2-b]quinoline-4-one 3-pinacolatoboro-6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta[c][1]benzopyran 8-Phenyl-6,7-dihydro-8H-5-oxa-dibenzo[a,h]azulene 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl 4-fluorobenzenesulfonate 2-(2-bromophenyl)-4,9-dihydrocyclohepta[b]pyran-4,9-dione 3-[(trifluoromethylsulfonyl)oxy]-6-oxo-8,9,10,11-tetrahydro-7H-cyclohepta[c][1]benzopyran 3-hydroxy-2-(3-methyl-butyl)-8,9,10,11-tetrahydro-7H-cyclohepta[c]chromen-6-one 6,7-dimethoxy-1-methyl-2-(2-oxo-2-(2-oxo-2H-chromen-3-yl)ethyl)-3,4-dihydroisoquinolin-2-ium bromide 2-butyl-3-hydroxy-8,9,10,11-tetrahydro-7H-cyclohepta[c]chromen-6-one Irosustat metabolite M17 3-methoxy-8,9,10,11-tetrahydro-7H-cyclohepta[c]chromen-6-one syn-1,2,3,4,5,6,10,11,12,13,14,15-dodecahydro-2,6-methano-11,15-methanodicycloocta<1,4,7>dioxaselenocine-1,10,18,19-tetraone (1S,8R,9R,12R)-10-Oxo-1,8-diphenyl-11-oxa-tricyclo[7.2.1.02,7]dodeca-2(7),3,5-triene-12-carboxylic acid methyl ester 3-Hydroxy-2-(4-dimethylaminophenyl)-4,9-dihydrocycloheptapyran-4,9-dione 5-Brom-3-aethoxycarbonyl-7-methyl-8-hydroxy-1-oxa-azulan-2-on 3-(tert-butyl-dimethyl-silanyloxy)-8,9,10,11-tetrahydro-7H-cyclohepta[c]chromen-6-one 2-(3-nitrophenyl)-4,9-dihydrocyclohepta[b]pyran-4,9-dione 3,4-dimethoxy-8,9,10,11-tetrahydro-7H-cyclohepta[c]chromen-6-one 3-oxo-9,10-dihydro-3H-2-oxa-phenanthrene-1-carboxylic acid tert-butylamide 2-(2-chlorophenyl)-4,9-dihydrocyclohepta[b]pyran-4,9-dione 6-bromo-2-(2-methoxyphenyl)-8-methylchromen-4-one 3,9-diamino-1,7-di[1',3'-dihydro-2'H-indol-2-one spiro]naphtho[2,1-6:6,5-6']dipyran-2,8-dicabonitrile 3-Chloro-4-diethylamino-5,6-dihydro-furo[2,3-h]chromen-2-one 3-[[3-(Chloromethyl)phenyl]cyclopropylmethyl]-5,6,7,8,9,10-hexahydro-4-hydroxy-2H-cycloocta[b]pyran-2-one 4-(Methyl-phenyl-amino)-3-phenyl-6,7-dihydro-5H-1-oxa-dibenzo[a,c]cyclohepten-2-one (E)-2-Amino-4,5-dihydro-4-oxo-indeno<1,2-b>pyran-3-carbaldoxim 3-Phenyl-4-pyrrolidin-1-yl-6,7-dihydro-5H-1-oxa-dibenzo[a,c]cyclohepten-2-one 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl 4-(tert-butyl)benzenesulfonate 4-(5-(1H-imidazol-1-yl)-3-methyl-1-phenyl-1H-pyrazol-4-yl)-2-amino-7-hydroxy-8-methyl-4H-chromene-3-carbonitrile 2-oxo-3-phenyl-2,6-dihydro-[1,3]oxazino[2,3-a]isoindol-5-ium-4-olate 1-butanoyl-7-butoxy-5-methoxy-7-phenyl-8-oxabenzo[c]bicyclo[3.2.1]octan-2-one 3-(4-iodophenyl)-4-(2-oxopropyl)-2-phenyl-3,4-dihydro-5H-chromeno[3,4-c]pyridin-5-one 2-(3,5-dichlorophenyl)-4,9-dihydrocyclohepta[b]pyran-4,9-dione 2-(2,5-dimethoxyphenyl)-4,9-dihydrocyclohepta[b]pyran-4,9-dione 2-(4-bromophenyl)-4,9-dihydrocyclohepta[b]pyran-4,9-dione 6,7,8,9-tetrahydro-5H-cyclohepta[b]pyran-2-one N-ethyl-3-hydroxy-N,N-dimethyl-5-{4-[(6-oxo-7,8,9,10-tetrahydro-6H-benzo[c]chromen-3-yl)oxy]butoxy}benzenaminium iodide Eschenmoser's α-pyrone 6-bromo-2-(2-bromophenyl)cyclohepta[b]pyran-4,9-dione 3-(7-[2,2']bithienyl-5-yl-2,3-dihydro-[1,4]thiazepin-5-yl)-4-hydroxy-6-methyl-pyran-2-one isobellendine 6,7,8,9-tetrahydro-4-hydroxy-3-(1-phenylpropyl)cycloheptapyran-2(5H)-one isatropolone C 6,8-Dibromo-2-(2-methoxyphenyl)cyclohepta[b]pyran-4,9-dione 13-Amino-11-(4-fluorophenyl)-3,5-dimethyl-7-oxo-4,14-dioxatricyclo[8.4.0.02,6]tetradeca-1(10),2,5,8,12-pentaene-12-carbonitrile